^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dexamethasone injection

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Steroid receptor agonist, GCR agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions (clinicaltrials.gov)
    P4, N=165, Completed, Stanford University | Recruiting --> Completed
    Trial completion • HEOR
    |
    dexamethasone injection
    3d
    SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=142, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Sep 2024 --> Mar 2025
    Trial completion date
    |
    lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection
    3d
    Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=38, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    pomalidomide • Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • dexamethasone injection
    3d
    SINE: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=100, Recruiting, University of Chicago | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    CRBN (Cereblon)
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone injection
    10d
    Dexamethasone in Total Knee Arthroplasty (clinicaltrials.gov)
    P4, N=404, Active, not recruiting, Rush University Medical Center | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    12d
    Incidence of Macular Edema in a Uveitis Population (clinicaltrials.gov)
    P=N/A, N=1550, Active, not recruiting, Aalborg University Hospital
    New trial
    |
    dexamethasone injection
    13d
    Pulsed Radiofrequency Ablation and Steroid Injections for the Treatment of Meralgia Paresthetica (clinicaltrials.gov)
    P=N/A, N=22, Active, not recruiting, Ankara City Hospital Bilkent
    New trial
    |
    dexamethasone injection
    13d
    Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis (clinicaltrials.gov)
    P4, N=80, Recruiting, University of California, Davis | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    13d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis (clinicaltrials.gov)
    P1/2, N=34, Completed, The First Hospital of Jilin University | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion • Trial completion date
    |
    pemetrexed • dexamethasone injection
    15d
    Exploratory study on a single-day low-dose dexamethasone combined with a single or double standard dose of netupitant palonosetron capsules for preventing nausea and vomiting in patients undergoing moderately to highly emetogenic chemotherapy (LD-NEPA1/2 study) (ChiCTR2400089311)
    P=N/A, N=164, Not yet recruiting, Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University
    New trial
    |
    Akynzeo oral (netupitant/palonesteron FDC) • dexamethasone injection
    19d
    Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study (ASH 2024)
    Pts received Isa (10 mg/kg IV) in the Isa-VRd arm and bortezomib (1.3 mg/m2 SC), lenalidomide (25 mg PO), and dexamethasone (20 mg IV/PO) in both arms. Isa-VRd followed by Isa-Rd led to greater depth of response of MRD-neg over time, with higher rates of MRD-neg at both the end of initiation and during maintenance compared with the control arm. Results from these analyses continue to demonstrate higher rates of sustMRD-neg over time at 10-5 and 10-6 sensitivity thresholds, and more pts retained MRD-neg status through maintenance phase. More pts had positive-to-negative conversions with Isa-VRd vs VRd, with conversion events increasing over the maintenance period.
    Clinical • P3 data • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc) • dexamethasone injection
    24d
    Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery (clinicaltrials.gov)
    P1, N=108, Completed, Ohio State University | Recruiting --> Completed | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    dexamethasone • dexamethasone injection
    26d
    AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P2, N=300, Suspended, National Cancer Institute (NCI) | N=550 --> 300
    Enrollment change • Combination therapy • Checkpoint inhibition
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    Opdivo (nivolumab) • cytarabine • Blincyto (blinatumomab) • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Hemady (dexamethasone tablets) • ABP 206 (nivolumab biosimilar) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    28d
    COSMIC: Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients (clinicaltrials.gov)
    P3, N=100, Recruiting, St. Joseph's Healthcare Hamilton | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: May 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    1m
    Proton-PANC: Study of Proton Therapy in Adjuvant Pancreatic Cancer (clinicaltrials.gov)
    P1, N=9, Completed, Georgetown University | Recruiting --> Completed | Trial completion date: Dec 2021 --> Nov 2023
    Trial completion • Trial completion date
    |
    oxaliplatin • irinotecan • dexamethasone injection • fosaprepitant • ondansetron intravenous
    1m
    A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=174, Terminated, Amgen | Phase classification: P1/2 --> P1
    Phase classification • Combination therapy
    |
    pomalidomide • pavurutamab (AMG 701) • dexamethasone injection
    1m
    Methylprednisolone Taper, Lower Extremity (clinicaltrials.gov)
    P4, N=200, Recruiting, Emory University | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection • methylprednisolone oral
    1m
    CHESS: Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1)
    |
    TP53 mutation • CD20 positive
    |
    Rituxan (rituximab) • cytarabine • oxaliplatin • Brukinsa (zanubrutinib) • dexamethasone injection
    1m
    Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) (clinicaltrials.gov)
    P2, N=36, Recruiting, Aaron Logan, MD | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Nov 2027 | Initiation date: Feb 2024 --> Oct 2024 | Trial primary completion date: May 2027 --> Nov 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • dexamethasone • dexamethasone injection
    2ms
    ALCYONE: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma (clinicaltrials.gov)
    P3, N=706, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    bortezomib • Darzalex (daratumumab) • prednisone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2ms
    Subconjunctival Administration of an Adeno-Associated Virus Expressing Stanniocalcin-1 Provides Sustained Intraocular Pressure Reduction in Mice. (PubMed, Ophthalmol Sci)
    Steroid-mediated ocular hypertension was induced in C57BL/6J mice with weekly injections of dexamethasone into the conjunctival fornix, and mice were then injected subconjunctivally with 6 × 109 VGs of ssAAV2-STC-1-FLAG or ssAAV2-GFP...Reduction in conjunctival TNFα was seen when comparing subconjunctivally delivered ssAAV2-STC-1-FLAG to daily topical latanoprost. Subconjunctival delivery of the STC-1 transgene with a vector system may represent a novel treatment strategy for sustained IOP reduction and improved ocular tolerability that also avoids the daily dosing requirements of currently available medications. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • STC1 (Stanniocalcin 1)
    |
    dexamethasone injection
    2ms
    Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2025 --> Oct 2024 | Trial primary completion date: Oct 2024 --> Feb 2024
    Trial completion date • Trial primary completion date
    |
    pomalidomide • Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • dexamethasone injection
    2ms
    Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=21 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Hemady (dexamethasone tablets) • azeliragon (TTP488) • dexamethasone injection
    2ms
    Clinical use of ultrasound-guided pterygopalatine ganglion block for refractory allergic rhinitis: a prospective, randomised controlled, single-blind, single-centre clinical study (ChiCTR2400088205)
    P=N/A, N=76, Completed, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan
    New trial
    |
    dexamethasone injection
    2ms
    Efficacy of aprepitant combined with dual antiemetics in preventing postoperative nausea and vomiting after sleeve gastrectomy: A single-center, randomized controlled trial (ChiCTR2400087798)
    P=N/A, N=276, Recruiting, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Sc
    New trial
    |
    aprepitant oral • dexamethasone injection • ondansetron
    2ms
    Ultrasound-Guided Thoracic Paravertebral Injection of Dexamethasone Palmitate Combined with Ropivacaine for the Treatment of Thoracic Herpes Zoster-Related Pain: A Prospective, Randomized Controlled, Single-Center Study (ChiCTR2400087273)
    P2, N=254, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
    New P2 trial
    |
    dexamethasone injection
    2ms
    A prospective, single-centre, randomised, parallel-controlled study of the early use of glucocorticoids after microvascular decompression of the facial nerve for the prevention of delayed facial palsy (ChiCTR2400088560)
    P1, N=226, Not yet recruiting, Xinhua Hospital Affilated to Shanghai Jiaotong University School of Medicine; Xinhua Hospital Affilated to Shanghai Jiaotong University School of Medi
    New P1 trial
    |
    prednisone • dexamethasone injection
    2ms
    BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron (clinicaltrials.gov)
    P4, N=90, Recruiting, University of Illinois at Chicago | Trial completion date: May 2024 --> Jul 2026 | Trial primary completion date: May 2024 --> Jul 2026
    Trial completion date • Trial primary completion date • HEOR
    |
    dexamethasone injection • ondansetron intravenous
    2ms
    A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). (PubMed, Ann Oncol)
    Olanzapine 5mg for 6 days with 5-HT3RA and dexamethasone appears effective for T-DXd-treated patients to prevent delayed and persistent nausea and vomiting.
    Clinical • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • dexamethasone injection • olanzapine
    2ms
    Comparison of the Effects of Intraoral Postoperative Dexamethasone Applications After Mandibular Third Molar Surgery (clinicaltrials.gov)
    P4, N=20, Completed, Afyonkarahisar Health Sciences University
    New P4 trial • Surgery
    |
    dexamethasone injection
    3ms
    Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19 (clinicaltrials.gov)
    P2/3, N=36, Completed, Materno-Perinatal Hospital of the State of Mexico
    New P2/3 trial
    |
    dexamethasone injection
    3ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1, N=189, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.
    Trial termination • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    3ms
    Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov)
    P1/2, N=62, Active, not recruiting, St. Jude Children's Research Hospital | Suspended --> Active, not recruiting
    Enrollment closed
    |
    IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • XIAP (X-Linked Inhibitor Of Apoptosis) • PRF1 (Perforin 1) • UNC13D (Unc-13 Homolog D) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • RAB27A (RAB27A, Member RAS Oncogene Family) • STXBP2 (Syntaxin Binding Protein 2)
    |
    Jakafi (ruxolitinib) • etoposide IV • dexamethasone injection
    3ms
    COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, University of Nebraska
    New P1/2 trial
    |
    dexamethasone injection
    3ms
    Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Emory University | Initiation date: Jul 2024 --> Oct 2024
    Trial initiation date
    |
    Hemady (dexamethasone tablets) • dexamethasone injection
    3ms
    The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF (clinicaltrials.gov)
    P3, N=33, Terminated, University of Nebraska | N=75 --> 33 | Recruiting --> Terminated; Poor compliance with data collection - too many intervals.
    Enrollment change • Trial termination
    |
    dexamethasone injection
    3ms
    Medical Versus Surgical Treatment for Peritonsillar Abscesses (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Nova Scotia Health Authority | N=24 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Head-to-Head
    |
    dexamethasone injection
    3ms
    DEXA-SEPSIS: Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis (clinicaltrials.gov)
    P1/2, N=102, Recruiting, CHA University | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection
    3ms
    FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (clinicaltrials.gov)
    P3, N=599, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone injection
    3ms
    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL (clinicaltrials.gov)
    P2, N=20, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • dexamethasone • Oncaspar liquid (pegaspargase) • dexamethasone injection • methotrexate IV
    3ms
    Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    3ms
    Pathological landscape of tumor flare reaction to epcoritamab treatment. (PubMed, Int J Hematol)
    This was identified as TFR, and was managed with a three-day course of intravenous dexamethasone at 12 mg/day. Although infrequent, TFR may be a significant indicator of tumor response to epcoritamab therapy. The diagnosis of TFR could be underestimated, and proper identification and understanding of its clinicopathological features are crucial for its effective management.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    Epkinly (epcoritamab-bysp) • dexamethasone injection